Pulmonary Drugs-Europe Market Status and Trend Report 2013-2023
Report Summary
Pulmonary Drugs-Europe Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Pulmonary Drugs industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole Europe and Regional Market Size of Pulmonary Drugs 2013-2017, and development forecast 2018-2023
Main market players of Pulmonary Drugs in Europe, with company and product introduction, position in the Pulmonary Drugs market
Market status and development trend of Pulmonary Drugs by types and applications
Cost and profit status of Pulmonary Drugs, and marketing status
Market growth drivers and challenges
The report segments the Europe Pulmonary Drugs market as:
Europe Pulmonary Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Germany
United Kingdom
France
Italy
Spain
Benelux
Russia
Europe Pulmonary Drugs Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Inhaled Corticosteroids (ICS)
Long-Acting Beta2-Agonists (LABA)
Antihistamine
Vasodilators
Short-Acting Beta2-Agonists (SABA)
Anticholinergics
Combination Drugs
MAbs
Enzymes
Antibiotics & Antileukotrienes
Europe Pulmonary Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Asthma & COPD
Allergic Rhinitis
Pulmonary Arterial Hypertension
Cystic Fibrosis
Europe Pulmonary Drugs Market: Players Segment Analysis (Company and Product introduction, Pulmonary Drugs Sales Volume, Revenue, Price and Gross Margin):
AstraZeneca plc
Bayer AG?
Teva Pharmaceutical Industries Ltd.?
Actelion Pharmaceuticals, Inc.
Boehringer Ingelheim GmbH
F. Hoffmann-La Roche Ltd.
Merck & Co., Inc.
Novartis AG
GlaxoSmithKline plc
Sunovion Pharmaceuticals, Inc.
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Pulmonary Drugs-Europe Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Pulmonary Drugs industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole Europe and Regional Market Size of Pulmonary Drugs 2013-2017, and development forecast 2018-2023
Main market players of Pulmonary Drugs in Europe, with company and product introduction, position in the Pulmonary Drugs market
Market status and development trend of Pulmonary Drugs by types and applications
Cost and profit status of Pulmonary Drugs, and marketing status
Market growth drivers and challenges
The report segments the Europe Pulmonary Drugs market as:
Europe Pulmonary Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Germany
United Kingdom
France
Italy
Spain
Benelux
Russia
Europe Pulmonary Drugs Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Inhaled Corticosteroids (ICS)
Long-Acting Beta2-Agonists (LABA)
Antihistamine
Vasodilators
Short-Acting Beta2-Agonists (SABA)
Anticholinergics
Combination Drugs
MAbs
Enzymes
Antibiotics & Antileukotrienes
Europe Pulmonary Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Asthma & COPD
Allergic Rhinitis
Pulmonary Arterial Hypertension
Cystic Fibrosis
Europe Pulmonary Drugs Market: Players Segment Analysis (Company and Product introduction, Pulmonary Drugs Sales Volume, Revenue, Price and Gross Margin):
AstraZeneca plc
Bayer AG?
Teva Pharmaceutical Industries Ltd.?
Actelion Pharmaceuticals, Inc.
Boehringer Ingelheim GmbH
F. Hoffmann-La Roche Ltd.
Merck & Co., Inc.
Novartis AG
GlaxoSmithKline plc
Sunovion Pharmaceuticals, Inc.
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF PULMONARY DRUGS
1.1 Definition of Pulmonary Drugs in This Report
1.2 Commercial Types of Pulmonary Drugs
1.2.1 Inhaled Corticosteroids (ICS)
1.2.2 Long-Acting Beta2-Agonists (LABA)
1.2.3 Antihistamine
1.2.4 Vasodilators
1.2.5 Short-Acting Beta2-Agonists (SABA)
1.2.6 Anticholinergics
1.2.7 Combination Drugs
1.2.8 MAbs
1.2.9 Enzymes
1.2.10 Antibiotics & Antileukotrienes
1.3 Downstream Application of Pulmonary Drugs
1.3.1 Asthma & COPD
1.3.2 Allergic Rhinitis
1.3.3 Pulmonary Arterial Hypertension
1.3.4 Cystic Fibrosis
1.4 Development History of Pulmonary Drugs
1.5 Market Status and Trend of Pulmonary Drugs 2013-2023
1.5.1 EMEA Pulmonary Drugs Market Status and Trend 2013-2023
1.5.2 Regional Pulmonary Drugs Market Status and Trend 2013-2023
CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Pulmonary Drugs in EMEA 2013-2017
2.2 Consumption Market of Pulmonary Drugs in EMEA by Regions
2.2.1 Consumption Volume of Pulmonary Drugs in EMEA by Regions
2.2.2 Revenue of Pulmonary Drugs in EMEA by Regions
2.3 Market Analysis of Pulmonary Drugs in EMEA by Regions
2.3.1 Market Analysis of Pulmonary Drugs in Europe 2013-2017
2.3.2 Market Analysis of Pulmonary Drugs in Middle East 2013-2017
2.3.3 Market Analysis of Pulmonary Drugs in Africa 2013-2017
2.4 Market Development Forecast of Pulmonary Drugs in EMEA 2018-2023
2.4.1 Market Development Forecast of Pulmonary Drugs in EMEA 2018-2023
2.4.2 Market Development Forecast of Pulmonary Drugs by Regions 2018-2023
CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES
3.1 Whole EMEA Market Status by Types
3.1.1 Consumption Volume of Pulmonary Drugs in EMEA by Types
3.1.2 Revenue of Pulmonary Drugs in EMEA by Types
3.2 EMEA Market Status by Types in Major Countries
3.2.1 Market Status by Types in Europe
3.2.2 Market Status by Types in Middle East
3.2.3 Market Status by Types in Africa
3.3 Market Forecast of Pulmonary Drugs in EMEA by Types
CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Pulmonary Drugs in EMEA by Downstream Industry
4.2 Demand Volume of Pulmonary Drugs by Downstream Industry in Major Countries
4.2.1 Demand Volume of Pulmonary Drugs by Downstream Industry in Europe
4.2.2 Demand Volume of Pulmonary Drugs by Downstream Industry in Middle East
4.2.3 Demand Volume of Pulmonary Drugs by Downstream Industry in Africa
4.3 Market Forecast of Pulmonary Drugs in EMEA by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF PULMONARY DRUGS
5.1 EMEA Economy Situation and Trend Overview
5.2 Pulmonary Drugs Downstream Industry Situation and Trend Overview
CHAPTER 6 PULMONARY DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA
6.1 Sales Volume of Pulmonary Drugs in EMEA by Major Players
6.2 Revenue of Pulmonary Drugs in EMEA by Major Players
6.3 Basic Information of Pulmonary Drugs by Major Players
6.3.1 Headquarters Location and Established Time of Pulmonary Drugs Major Players
6.3.2 Employees and Revenue Level of Pulmonary Drugs Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 PULMONARY DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 AstraZeneca plc
7.1.1 Company profile
7.1.2 Representative Pulmonary Drugs Product
7.1.3 Pulmonary Drugs Sales, Revenue, Price and Gross Margin of AstraZeneca plc
7.2 Bayer AG?
7.2.1 Company profile
7.2.2 Representative Pulmonary Drugs Product
7.2.3 Pulmonary Drugs Sales, Revenue, Price and Gross Margin of Bayer AG?
7.3 Teva Pharmaceutical Industries Ltd.?
7.3.1 Company profile
7.3.2 Representative Pulmonary Drugs Product
7.3.3 Pulmonary Drugs Sales, Revenue, Price and Gross Margin of Teva Pharmaceutical Industries Ltd.?
7.4 Actelion Pharmaceuticals, Inc.
7.4.1 Company profile
7.4.2 Representative Pulmonary Drugs Product
7.4.3 Pulmonary Drugs Sales, Revenue, Price and Gross Margin of Actelion Pharmaceuticals, Inc.
7.5 Boehringer Ingelheim GmbH
7.5.1 Company profile
7.5.2 Representative Pulmonary Drugs Product
7.5.3 Pulmonary Drugs Sales, Revenue, Price and Gross Margin of Boehringer Ingelheim GmbH
7.6 F. Hoffmann-La Roche Ltd.
7.6.1 Company profile
7.6.2 Representative Pulmonary Drugs Product
7.6.3 Pulmonary Drugs Sales, Revenue, Price and Gross Margin of F. Hoffmann-La Roche Ltd.
7.7 Merck & Co., Inc.
7.7.1 Company profile
7.7.2 Representative Pulmonary Drugs Product
7.7.3 Pulmonary Drugs Sales, Revenue, Price and Gross Margin of Merck & Co., Inc.
7.8 Novartis AG
7.8.1 Company profile
7.8.2 Representative Pulmonary Drugs Product
7.8.3 Pulmonary Drugs Sales, Revenue, Price and Gross Margin of Novartis AG
7.9 GlaxoSmithKline plc
7.9.1 Company profile
7.9.2 Representative Pulmonary Drugs Product
7.9.3 Pulmonary Drugs Sales, Revenue, Price and Gross Margin of GlaxoSmithKline plc
7.10 Sunovion Pharmaceuticals, Inc.
7.10.1 Company profile
7.10.2 Representative Pulmonary Drugs Product
7.10.3 Pulmonary Drugs Sales, Revenue, Price and Gross Margin of Sunovion Pharmaceuticals, Inc.
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF PULMONARY DRUGS
8.1 Industry Chain of Pulmonary Drugs
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF PULMONARY DRUGS
9.1 Cost Structure Analysis of Pulmonary Drugs
9.2 Raw Materials Cost Analysis of Pulmonary Drugs
9.3 Labor Cost Analysis of Pulmonary Drugs
9.4 Manufacturing Expenses Analysis of Pulmonary Drugs
CHAPTER 10 MARKETING STATUS ANALYSIS OF PULMONARY DRUGS
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
1.1 Definition of Pulmonary Drugs in This Report
1.2 Commercial Types of Pulmonary Drugs
1.2.1 Inhaled Corticosteroids (ICS)
1.2.2 Long-Acting Beta2-Agonists (LABA)
1.2.3 Antihistamine
1.2.4 Vasodilators
1.2.5 Short-Acting Beta2-Agonists (SABA)
1.2.6 Anticholinergics
1.2.7 Combination Drugs
1.2.8 MAbs
1.2.9 Enzymes
1.2.10 Antibiotics & Antileukotrienes
1.3 Downstream Application of Pulmonary Drugs
1.3.1 Asthma & COPD
1.3.2 Allergic Rhinitis
1.3.3 Pulmonary Arterial Hypertension
1.3.4 Cystic Fibrosis
1.4 Development History of Pulmonary Drugs
1.5 Market Status and Trend of Pulmonary Drugs 2013-2023
1.5.1 EMEA Pulmonary Drugs Market Status and Trend 2013-2023
1.5.2 Regional Pulmonary Drugs Market Status and Trend 2013-2023
CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Pulmonary Drugs in EMEA 2013-2017
2.2 Consumption Market of Pulmonary Drugs in EMEA by Regions
2.2.1 Consumption Volume of Pulmonary Drugs in EMEA by Regions
2.2.2 Revenue of Pulmonary Drugs in EMEA by Regions
2.3 Market Analysis of Pulmonary Drugs in EMEA by Regions
2.3.1 Market Analysis of Pulmonary Drugs in Europe 2013-2017
2.3.2 Market Analysis of Pulmonary Drugs in Middle East 2013-2017
2.3.3 Market Analysis of Pulmonary Drugs in Africa 2013-2017
2.4 Market Development Forecast of Pulmonary Drugs in EMEA 2018-2023
2.4.1 Market Development Forecast of Pulmonary Drugs in EMEA 2018-2023
2.4.2 Market Development Forecast of Pulmonary Drugs by Regions 2018-2023
CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES
3.1 Whole EMEA Market Status by Types
3.1.1 Consumption Volume of Pulmonary Drugs in EMEA by Types
3.1.2 Revenue of Pulmonary Drugs in EMEA by Types
3.2 EMEA Market Status by Types in Major Countries
3.2.1 Market Status by Types in Europe
3.2.2 Market Status by Types in Middle East
3.2.3 Market Status by Types in Africa
3.3 Market Forecast of Pulmonary Drugs in EMEA by Types
CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Pulmonary Drugs in EMEA by Downstream Industry
4.2 Demand Volume of Pulmonary Drugs by Downstream Industry in Major Countries
4.2.1 Demand Volume of Pulmonary Drugs by Downstream Industry in Europe
4.2.2 Demand Volume of Pulmonary Drugs by Downstream Industry in Middle East
4.2.3 Demand Volume of Pulmonary Drugs by Downstream Industry in Africa
4.3 Market Forecast of Pulmonary Drugs in EMEA by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF PULMONARY DRUGS
5.1 EMEA Economy Situation and Trend Overview
5.2 Pulmonary Drugs Downstream Industry Situation and Trend Overview
CHAPTER 6 PULMONARY DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA
6.1 Sales Volume of Pulmonary Drugs in EMEA by Major Players
6.2 Revenue of Pulmonary Drugs in EMEA by Major Players
6.3 Basic Information of Pulmonary Drugs by Major Players
6.3.1 Headquarters Location and Established Time of Pulmonary Drugs Major Players
6.3.2 Employees and Revenue Level of Pulmonary Drugs Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 PULMONARY DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 AstraZeneca plc
7.1.1 Company profile
7.1.2 Representative Pulmonary Drugs Product
7.1.3 Pulmonary Drugs Sales, Revenue, Price and Gross Margin of AstraZeneca plc
7.2 Bayer AG?
7.2.1 Company profile
7.2.2 Representative Pulmonary Drugs Product
7.2.3 Pulmonary Drugs Sales, Revenue, Price and Gross Margin of Bayer AG?
7.3 Teva Pharmaceutical Industries Ltd.?
7.3.1 Company profile
7.3.2 Representative Pulmonary Drugs Product
7.3.3 Pulmonary Drugs Sales, Revenue, Price and Gross Margin of Teva Pharmaceutical Industries Ltd.?
7.4 Actelion Pharmaceuticals, Inc.
7.4.1 Company profile
7.4.2 Representative Pulmonary Drugs Product
7.4.3 Pulmonary Drugs Sales, Revenue, Price and Gross Margin of Actelion Pharmaceuticals, Inc.
7.5 Boehringer Ingelheim GmbH
7.5.1 Company profile
7.5.2 Representative Pulmonary Drugs Product
7.5.3 Pulmonary Drugs Sales, Revenue, Price and Gross Margin of Boehringer Ingelheim GmbH
7.6 F. Hoffmann-La Roche Ltd.
7.6.1 Company profile
7.6.2 Representative Pulmonary Drugs Product
7.6.3 Pulmonary Drugs Sales, Revenue, Price and Gross Margin of F. Hoffmann-La Roche Ltd.
7.7 Merck & Co., Inc.
7.7.1 Company profile
7.7.2 Representative Pulmonary Drugs Product
7.7.3 Pulmonary Drugs Sales, Revenue, Price and Gross Margin of Merck & Co., Inc.
7.8 Novartis AG
7.8.1 Company profile
7.8.2 Representative Pulmonary Drugs Product
7.8.3 Pulmonary Drugs Sales, Revenue, Price and Gross Margin of Novartis AG
7.9 GlaxoSmithKline plc
7.9.1 Company profile
7.9.2 Representative Pulmonary Drugs Product
7.9.3 Pulmonary Drugs Sales, Revenue, Price and Gross Margin of GlaxoSmithKline plc
7.10 Sunovion Pharmaceuticals, Inc.
7.10.1 Company profile
7.10.2 Representative Pulmonary Drugs Product
7.10.3 Pulmonary Drugs Sales, Revenue, Price and Gross Margin of Sunovion Pharmaceuticals, Inc.
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF PULMONARY DRUGS
8.1 Industry Chain of Pulmonary Drugs
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF PULMONARY DRUGS
9.1 Cost Structure Analysis of Pulmonary Drugs
9.2 Raw Materials Cost Analysis of Pulmonary Drugs
9.3 Labor Cost Analysis of Pulmonary Drugs
9.4 Manufacturing Expenses Analysis of Pulmonary Drugs
CHAPTER 10 MARKETING STATUS ANALYSIS OF PULMONARY DRUGS
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
